Georgina Fröhlich

Dr. Georgina Fröhlich

Centre of Radiotherapy, National Institute of Oncology, Budapest, Hungary
+1
orcid
Medical Physicist Expert | Associate Professor

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2021 in Strahlentherapie und Onkologie
Verified
Journal Article
Open access
PDF file
TMTibor Major
Tibor Major
Georgina FröhlichGeorgina Fröhlich
Georgina Fröhlich
PÁPéter Ágoston
Péter Ágoston
CPCsaba Polgár
Csaba Polgár
ZTZoltán Takácsi-Nagy
Zoltán Takácsi-Nagy
Brachytherapy (BT) has long been used for successful treatment of various tumour entities, including prostate, breast and gynaecological cancer. However, particularly due to advances in modern external beam techniques such as intensity-modulated radiotherapy (IMRT), volume modulated arc therapy (VMAT) and stereotactic body radiotherapy (SBRT), there are concerns about its future. Based on a comprehensive literature review, this article aims to summarize the role of BT in cancer treatment and highlight its particular dosimetric advantages. The authors conclude that image-guided BT supported by inverse dose planning will successfully compete with high-tech EBRT in the future and continue to serve as a valuable modality for cancer treatment.

3 September 2019 in Strahlentherapie und Onkologie
Verified
Journal Article
Open access
PDF file
Georgina FröhlichGeorgina Fröhlich
Georgina Fröhlich
GGGyula Geszti
Gyula Geszti
JVJúlia Vízkeleti
Júlia Vízkeleti
PÁPéter Ágoston
Péter Ágoston
CPCsaba Polgár
Csaba Polgár
TMTibor Major
Tibor Major
Dosimetric comparison of HIPO (hybrid inverse planning optimisation) and IPSA (inverse planning simulated annealing) inverse and forward optimisation (FO) methods in brachytherapy (BT) of breast, cervical and prostate cancer.

14 February 2022 in Strahlentherapie und Onkologie
Verified
Journal Article
Open access
PDF file
ZTZoltán Takácsi-Nagy
Zoltán Takácsi-Nagy
ÖFÖrs Ferenczi
Örs Ferenczi
TMTibor Major
Tibor Major
HAHironori Akiyama
Hironori Akiyama
Georgina FröhlichGeorgina Fröhlich
Georgina Fröhlich
CPCsaba Polgár
Csaba Polgár
Purpose: To describe the results of treating tongue cancer patients with single postoperative interstitial, high-dose-rate (HDR) brachytherapy (BT) after resection.Methods: Between January 1998 and April 2019, 45 patients with squamous cell histology, stage T1–2N0–1M0 tongue tumours were treated by surgery followed by a single HDR BT in case of negative prognostic factors (close or positive surgical margin, lymphovascular and/or perineural invasion). The average dose was 29 Gy (range: 10–45 Gy) and rigid metal needles were used in 11 (24%) and flexible plastic catheters in 34 cases (76%). Survival parameters, toxicities and the prognostic factors influencing survival were analysed.Results: During a mean follow-up of 103 months (range: 16–260 months) for surviving patients, the 10-year local and regional control (LC, RC), overall survival (OS), and disease-specific survival (DSS) probabilities were 85, 73, 34 and 63%, respectively. The incidence of local grade 1, 2 and 3 mucositis was 23, 73 and 4%, respectively. As a serious (grade 4), late side effect, soft tissue necrosis developed in 3 cases (7%). In a univariate analysis, there was a significant correlation between lymphovascular invasion and RC (p = 0.0118) as well as cervical recurrence and DSS (p < 0.0001).Conclusion: Sole postoperative HDR brachytherapy can be an effective method in case of negative prognostic factors in the treatment of early, resectable tongue tumours. Comparing the results of patients treated with postoperative BT to those who were managed with surgery or BT alone known from the literature, a slightly more favourable LC can be achieved with the combination therapy, demonstrating the potential compensating effect of BT on adverse prognostic factors, while the developing severe, grade 4 toxicity rate remains low.

24 June 2010 in Strahlentherapie und Onkologie
Verified
Journal Article
Closed access
PDF file
Georgina FröhlichGeorgina Fröhlich
Georgina Fröhlich
PÁPéter Ágoston
Péter Ágoston
JLJózsef Lövey
József Lövey
ASAndrás Somogyi
András Somogyi
JFJános Fodor
János Fodor
TMTibor Major
Tibor Major

1 January 2019 in Journal of Contemporary Brachytherapy
Verified
Journal Article
Open access
PDF file
Georgina FröhlichGeorgina Fröhlich
Georgina Fröhlich
JVJúlia Vízkeleti
Júlia Vízkeleti
ANAnhhong Nhung Nguyen
Anhhong Nhung Nguyen
TMTibor Major
Tibor Major
CPCsaba Polgár
Csaba Polgár
Purpose To compare image-guided adaptive interstitial brachytherapy (BT) and intensity-modulated arc therapy (IMAT) with conventional treatment techniques in cervical cancer using an alternative biological dose summation method. Material and methods Initially, 21 interstitial BT and IMAT...

1 March 2019 in Reports of Practical Oncology and Radiotherapy
Verified
Journal Article
Closed access
Georgina FröhlichGeorgina Fröhlich
Georgina Fröhlich
KKKinga Dóra Kovács
Kinga Dóra Kovács
TMTibor Major
Tibor Major
CPCsaba Polgár
Csaba Polgár
To investigate the feasibility of in vivo rectal dosimetry in image-guided adaptive brachytherapy of cervical cancer. Error of measurement of dose rate in a semiconductor diode probe was investigated depending on the distance and angle in water, and on temperature in a polymethyl methacrylate phantom using an Ir-192 source. Furthermore, the difference between the measured and calculated dose was analysed in the interstitial brachytherapy of 30 cervix cancer patients. The relationship between in vivo measured dose, calculated dose in the point of the diode, calculated maximal dose in the point of the diodes and calculated maximal dose of the rectum were examined. The dosimeter measured with 85% accuracy at more than 5 cm from the source, but within a closer distance the accuracy decreased significantly. At 45-90° angle, the device measured with a 15% error. The error increased with the temperature, 22% at 35 °C. In 8 cases (26.7%) the maximal dose was measured in the correct diode. The device measured 73% of the calculated dose in the point of the diode. The maximum of the calculated doses of diodes was 60% of the calculated maximal dose. The in vivo measured dose was 35% of the calculated maximal dose. Under treatment conditions, the semiconductor diode does not provide reliable measured data. The probe pushes the rectal wall closer to the high dose areas and underestimates the dose of it. Semiconductor probe is not recommended for in vivo dosimetry of the rectum in image-guided brachytherapy of cervical cancer.